MD Anderson Researchers Unveil Blood-Based T Cell Biomarker to Predict Cancer Risk in Lynch Syndrome "Previvors"

Researchers discover a blood-based T cell signature that detects early cancer risk in Lynch Syndrome carriers, enabling personalized non-invasive monitoring.

By: AXL Media

Published: Apr 7, 2026, 6:06 AM EDT

Source: Information for this report was sourced from University of Texas M. D. Anderson Cancer Center

The Challenge of Lynch Syndrome Surveillance

Lynch Syndrome is a hereditary condition caused by germline mutations in DNA mismatch repair genes, significantly increasing the lifetime risk of developing cancers with microsatellite instability. Patients with LS often face cancer diagnoses at a much younger age than the general population, requiring aggressive and frequent invasive screenings. To address this, a team led by Eduardo Vilar-Sanchez, M.D., Ph.D., sought a "liquid biopsy" approach to monitor the immune system's internal battle against emerging pre-cancerous cells.

Mapping the Immune "Recognition" Patterns

The research, published in Nature Communications, centers on the relationship between microsatellite mutations and the immune system. These genetic mutations create tumor-specific neoantigens—protein fragments that T cells recognize as foreign. By sequencing T cell receptors (TCRs) from the blood of 277 participants—including LS survivors, "previvors" (carriers without a history of cancer), and healthy controls—the team was able to identify specific TCR patterns that expand in response to these early cancer signals.

A Non-Invasive Signature for Early Detection

The study’s findings were striking: up to 41% of the expanded TCRs found in colon tumors and pre-cancers were also detectable in the peripheral blood of LS carriers, but were entirely absent in those without the syndrome. This suggests that the immune system in LS patients is in a constant state of surveillance, reacting to early-stage mutations long before they become clinically detectable tumors. Using this data, the researchers developed a classification model capable of identifying LS carriers simply by analyzing TCR patterns in a standard blood sample.